Next Article in Journal
Manipulating Enzymes Properties with DNA Nanostructures
Next Article in Special Issue
Silymarin and Cancer: A Dual Strategy in Both in Chemoprevention and Chemosensitivity
Previous Article in Journal
Antibacterial and Antifungal Activity of Three Monosaccharide Monomyristate Derivatives
Previous Article in Special Issue
Formulation Strategies for Enhancing the Bioavailability of Silymarin: The State of the Art
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Molecules
Volume 24
Issue 20
10.3390/molecules24203693
Review Report
molecules-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles
Review
Peer-Review Record

Metabolism, Transport and Drug–Drug Interactions of Silymarin

Molecules 2019, 24(20), 3693; https://doi.org/10.3390/molecules24203693
by Ying Xie *, Dingqi Zhang, Jin Zhang and Jialu Yuan
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Molecules 2019, 24(20), 3693; https://doi.org/10.3390/molecules24203693
Submission received: 27 September 2019 / Revised: 11 October 2019 / Accepted: 14 October 2019 / Published: 14 October 2019
(This article belongs to the Special Issue Silymarin and Derivatives: From Biosynthesis to Health Benefits)

Round 1

Reviewer 1 Report

This is an interesting manuscript where the latest research on silybin metabolism is reported. The manuscript is well-read and has a logical sound. It highlights the metabolism of this interesting natural molecule by highlighting all its applications as a natural drug.

The authors should report in the introduction of the latest findings on silybin. Recently in vivo and in vitro studies have shown the ability of silybin (doi:10.1021/acschemneuro.7b00110) to inhibit the toxicity of Abeta (1-49), the polypeptide responsible for Alzheimer's disease (doi:10.1016/j.bbamem.2018.02.022). I suggest inserting this finding after describing diabetes since these diseases are interacting. English should be improved.

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Reviewer 2 Report

This review describes the fate of silymarin in human organism.
1. Introduction : it is not easy for the reader who discovers silymarin in this paper to understand that silymarin designates a mixture of flavanolignans. The word "silibinin" designates the 2 diastereomers silybin A and silybin B, whereas other flavanolignans such as isosilybin A and B, silydianin and silychristin are also present in silymarin. This could be clearly explained.
2. Page 5, line 121 (end of paragraph on tangeretin) : the reference 20 by Yuan et al (2018) may be cited.
3. Page 6, lines 152-159 (§ 4.1) : the concentrations of silybin should be always in the same unit; this would be easier to compare the concentrations.
4. Page 6,line 165 : Legalon® is a trade mark, so it should have a «®».
5. Page 6, lines 170-177 : do the authors have an explanation for the contradictory results regarding the interaction of silybin with the different CYPs in humans and animals ?
6. Page 7, line 214 : replace "exaction" by "extract".
7. Page 8, line 205 : spelling mistake : P-gp
8. English should be improved.

Author Response

Please see the attachment

Author Response File: Author Response.pdf

Back to TopTop